2018
DOI: 10.1186/s41824-018-0043-1
|View full text |Cite
|
Sign up to set email alerts
|

Tumor heterogeneity measurement using [18F] FDG PET/CT shows prognostic value in patients with non-small cell lung cancer

Abstract: Background: The aim of this study was to evaluate primary tumor heterogeneity in patients with FDG-avid non-small cell lung cancer on PET/CT, with a view to optimising prognostic information from the metabolic signature of the primary tumor. Methods: A retrospective analysis of 94 [ 18 F] FDG PET/CTs (56 M:38F) in patients with a diagnosis of primary lung malignancy was performed. Data collected included patient demographics, tumor size, maximum standardized uptake value (SUVmax), clinical stage and tumor hist… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
3
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 6 publications
(3 citation statements)
references
References 13 publications
(14 reference statements)
0
3
0
Order By: Relevance
“…However, whilst clinically useful, a single SUV value cannot capture all of the relevant information within the tumour. Assessing tumour heterogeneity in SUV values in non-small cell lung carcinoma patients, the latter was found to be an independent predictor of overall survival in NSCLC cancer patients in multivariable analysis in a study by Hughes et al [25]. In their study, tumour heterogeneity was evaluated as the percentage variance unexplained in the tumour region-of-interest uptake values using an ellipsoidally contoured model and a homogenous tumour mass whose voxel intensity is greatest at the centre and diminishes in a monotone fashion as one moves radially towards the periphery of the tumour for comparison.…”
Section: Discussionmentioning
confidence: 99%
“…However, whilst clinically useful, a single SUV value cannot capture all of the relevant information within the tumour. Assessing tumour heterogeneity in SUV values in non-small cell lung carcinoma patients, the latter was found to be an independent predictor of overall survival in NSCLC cancer patients in multivariable analysis in a study by Hughes et al [25]. In their study, tumour heterogeneity was evaluated as the percentage variance unexplained in the tumour region-of-interest uptake values using an ellipsoidally contoured model and a homogenous tumour mass whose voxel intensity is greatest at the centre and diminishes in a monotone fashion as one moves radially towards the periphery of the tumour for comparison.…”
Section: Discussionmentioning
confidence: 99%
“…Brain tumours typically exhibit numerous genetic mutations, spanning several cellular pathways, that open multiple avenues to oncogenesis no single intervention could conceivably block. It is no surprise that patients with higher levels of tumour heterogeneity—ranging across genetic, 4 , 8 , 9 epigenetic, cellular and imaging characteristics 10 , 11 —exhibit both poorer clinical outcomes and weaker responses to therapy. 5 , 12-14 …”
Section: Introductionmentioning
confidence: 99%
“…Here we consider the former approach, analyzing the volumetric uptake in function of an idealized ellipsoidal pattern. This was initially built upon clinical experience in sarcoma and has demonstrated prognostic utility in a number of diseases [13], [15] including NSCLC [16], [17]. This spatial modeling technique provides an assessment of the structure of the FDG uptake distribution, and allows deriving other associated variables of interest, such as metabolic gradients [15], [18].…”
mentioning
confidence: 99%